bladder adenocarcinoma
Conditions
Interventions
Administration of oxaliplatin, fluorouracil, levofolinate and bevacizumab
Sponsors
Nagoya City University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.The patients who have a diagnosis of a bladder adenocarcinoma histologically 2.The patients who are resistant to clinical trial S1+CDDP for the bladder adenocarcinoma and GD therapy of 2nd line for the urothelial carcinoma. 3.The patients who do not use bebacizumab
Exclusion criteria
Exclusion criteria: 1.Case with serious myelosuppression 2.Case with the diarrhea (stools watery) 3.Case who had a serious infection 4.A large quantity of ascitic fluid, case with the pleural effusion 5.Case with serious heart disease or the anamnesis 6.The case that overall status worsens 7.Case with severe dysesthesia with the functional disorder or the dysesthesia 8.A pregnant woman or the case that may be pregnant and nursing mother 9.It is a case with a history of hypersensitivity for an ingredient including, levofolinate, fluorouracil, oxaliplatin and other platinum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Countries
Japan
Contacts
Public ContactNoriyasu Kawai
Nagoya City University Graduate School of Medical Sciences Department of Nephro-urology
Outcome results
None listed